Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2006 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer.
Journal Article Clin Lung Cancer · January 26, 2026 INTRODUCTION: Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive malignancy with limited treatment options and poor outcomes. Despite the addition of antiprogrammed death ligand 1 inhibitors to platinum-etoposide chemotherapy, median overall ... Full text Link to item CiteLRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.
Journal Article Clin Cancer Res · December 15, 2025 PURPOSE: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), and overall survival with immune checkpoint inhibitio ... Full text Link to item CitePerioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.
Journal Article J Immunother Cancer · October 31, 2025 PURPOSE: A recently published phase 2 neoadjuvant trial in patients with early-stage non-small cell lung cancer (NSCLC) (NCT02818920) evaluated the potential efficacy of pembrolizumab administration in the absence of chemotherapy. This communication report ... Full text Link to item CiteRecent Grants
Safety, Efficacy, and Tumor Immune Microenvironment Changes with Neoadjuvant Chemotherapy and Cemiplimab with or without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2030Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study, C4221026); Encorafenib and Binimetinib Continuation Sub-Study for Participants From the C4221008 (ARRAY-818-202; PHAROS) Study (C4221008C)
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2025 - 2030A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2025 - 2030View All Grants
Education, Training & Certifications
Vanderbilt University ·
1986
M.D.
University of California, Irvine ·
1983
Ph.D.